Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drinabant - Opiant Pharmaceuticals

Drug Profile

Drinabant - Opiant Pharmaceuticals

Alternative Names: AVE 1625; INDV-5004; OPNT-004

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Opiant Pharmaceuticals; sanofi-aventis
  • Class Antidementias; Antihyperglycaemics; Antiparkinsonians; Antipsychotics; Halogenated hydrocarbons; Obesity therapies; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Substance-related disorders
  • Discontinued Alzheimer's disease; Obesity; Parkinson's disease; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 02 Mar 2023 Opiant Pharmaceuticals has been acquired by Indivior
  • 27 Dec 2022 Preclinical development is ongoing in USA (Parenteral) (Opiant Pharmaceuticals pipeline, December 2022)
  • 22 Aug 2022 Opiant Pharmaceuticals receives patent allowance for drinabant for the treatment of cannabinoid hyperemesis syndrome in US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top